News und Analysen
Here's Why ViewRay, Inc. Is Rising Today
After the company announced that it has received orders for a pair of MRIdian Linac systems, shares of ViewRay (NASDAQ: VRAY), a small-cap company focused on radiation therapy, jumped 17% as of....
Here's Why Cerus Corporation Rose as Much as 23.6% Today
Shares of biomedical products company Cerus Corporation (NASDAQ: CERS) jumped over 21% this morning, after the company released third-quarter 2017 financial results following market close....
Here's Why Pacific Biosciences of California Is Getting Hammered Today
Shares of DNA-sequencing pioneer Pacific Biosciences of California (NASDAQ: PACB) fell as much as 21.6% this morning after the company missed third-quarter revenue estimates by a mile. While....
Here's Why Insulet Corporation's Investors Are Pumped
In response to the company's upbeat third-quarter results and raised guidance, shares of Insulet Corporation (NASDAQ: PODD), a medical device maker focused on diabetes and drug delivery, rose 16%....
Why This Marijuana Stock Didn't Sink Despite a Huge Earnings Miss
Wall Street analysts expected Insys Therapeutics (NASDAQ: INSY) to report dismal third-quarter results. But they didn't know just how bad those results would actually be.Insys announced its....
Why Investors Are Paying a Premium for EXACT Sciences Corporation
EXACT Sciences Corporation (NASDAQ: EXAS) operates in an industry famous for cutthroat competition that strangles profitability. In this context, the stock's 300% run-up to a nosebleed-inducing....
Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales
Insulet (NASDAQ: PODD) reported solid third-quarter 2017 financial results after the market closed on Thursday. The drug delivery company, which is a leader in tubeless insulin pump technology....
Pacific Biosciences of California Posts Big Third Quarter Loss
So far in 2017, Pacific Biosciences of California (NASDAQ: PACB), also known as PacBio, has yet to report impressive quarterly results. In August, the genetic-sequencing company reported big....
3 Reasons Behind Exelixis Stock's Big Bounce
After experiencing a dismal September and sliding quite a bit over the last few weeks after a rebound, Exelixis (NASDAQ: EXEL) stock enjoyed a big bounce on Thursday. The biotech announced its....
3 Reasons It's Smart to Buy Celgene's Stock Now
Celgene Corp. (NASDAQ: CELG) shares nose-dived in October following a trial failure and third-quarter financials that failed to impress. However, there are good reasons investors ought to consider....
The Precision Medicine Stock That's Revolutionizing Cancer Treatment
Foundation Medicine's (NASDAQ: FMI) genetic screening tests are leading the way in discovering what medicines will work best in cancer patients based on their DNA. As more specialized drugs....
Here's Why Idera Pharmaceuticals Jumped as Much as 11.5% Today
Shares of clinical-stage biopharma Idera Pharmaceuticals (NASDAQ: IDRA) jumped over 11% today without any company-specific news. Why? The two leading RNA-based genetic medicine companies were....
Here's Why bluebird bio Inc. Is Surging Again Today
Shares of bluebird bio Inc. (NASDAQ: BLUE), a clinical-stage biotech developing cell-based therapies, are on the move for the second day in a row. Yesterday, the stock jumped in response to a....
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
On the surface, IDEXX Laboratories's (NASDAQ: IDXX) third quarter wasn't the kind of outstanding report we've come to expect from the animal-testing company, which narrowed its revenue guidance....
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
On the surface, IDEXX Laboratories's (NASDAQ: IDXX) third quarter wasn't the kind of outstanding report we've come to expect from the animal-testing company, which narrowed its revenue guidance....
IDEXX Laboratories, Inc. Puts Long-Term Profits Ahead of Short-Term Revenue
On the surface, IDEXX Laboratories's (NASDAQ: IDXX) third quarter wasn't the kind of outstanding report we've come to expect from the animal-testing company, which narrowed its revenue guidance....
The Clear Reason Exelixis, Inc. Rocketed Higher by as Much as 10%
Shares of Exelixis (NASDAQ: EXEL), a mid-cap drug developer with a focus on novel cancer therapies, rocketed higher by as much as 10% during Thursday's trading session after the company reported....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
What's Behind Gilead Sciences Inc.'s $7.8 Billion Slide in October?
Shares of Gilead Sciences, Inc. (NASDAQ: GILD) slipped 7.5% last month, according to S&P Global Market Intelligence, reducing the biotech's market cap by $7.8 billion. Although the company....
Here's Why Alnylam's Gain Is Ionis Pharmaceuticals' Loss Today
As of 1:18 p.m. EDT on Thursday, shares of Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) are up 13.7%, while shares of its biotech peer Ionis Pharmaceuticals Inc. (NASDAQ: IONS) are down....
Is This Why OraSure Technologies, Inc. Is Tanking Today?
Shares of OraSure Technologies (NASDAQ: OSUR), a healthcare company focused on diagnostic products and specimen-collection devices, dropped after the company reported third-quarter earnings. As of....
Here's Why Myriad Genetics Dropped as Much as 18.6%
Shares of genetic-testing leader Myriad Genetics (NASDAQ: MYGN) dropped over 18% today. That may have investors confused, especially considering the company today announced that its GeneSight....
Here's Why Intellia Therapeutics Sank as Much as 17.7% Today
Shares of CRISPR gene-editing biopharma Intellia Therapeutics (NASDAQ: NTLA) dropped nearly 18% today after the company announced a major public share offering to increase its cash balance. The....
Here's Why Neurocrine Biosciences Is Soaring
In response to the company reporting better-than-expected quarterly results, shares of Neurocrine Biosciences (NASDAQ: NBIX), a commercial stage biotech focused on neurological and endocrine....